Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective
Schultz K, Chintagumpala M, Piao J, Chen K, Shah R, Gartrell R, Christison-Lagay E, Pashnakar F, Berry J, O'Neill A, Vasta L, Flynn A, Mitchell S, Seynnaeve B, Rosenblum J, Potter S, Kamihara J, Rodriguez-Galindo C, Hawkins D, Laetsch T. Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective. 2023, 2: 100024. PMID: 37829670, PMCID: PMC10566015, DOI: 10.1016/j.ejcped.2023.100024.Peer-Reviewed Original ResearchTumor CommitteeStromal tumorsDesmoplastic small round cell tumorSmall round cell tumorGastrointestinal stromal tumorsNonmelanoma skin cancerRound cell tumorGonadal stromal tumorPleuropulmonary blastomaRare tumorAdrenocortical carcinomaNeuroendocrine tumorsCell tumorsRare cancersChildhood cancerColorectal carcinomaPancreatic tumorsNasopharyngeal carcinomaThyroid carcinomaHigh-quality researchCarcinomaSkin cancerTumorsYoung adultsCancerImplications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee
Talbot L, Lautz T, Aldrink J, Ehrlich P, Dasgupta R, Mattei P, Tracy E, Glick R, Grant C, Brown E, Christison-Lagay E, Rodeberg D. Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee. Journal Of Pediatric Surgery 2023, 58: 2119-2127. PMID: 37550134, DOI: 10.1016/j.jpedsurg.2023.07.001.Peer-Reviewed Original ResearchAPSA Cancer CommitteeClass of immunotherapyT-cell therapyCancer CommitteePediatric malignanciesChimeric antigen receptor T-cell therapyMonoclonal antibody checkpoint inhibitorsTransgenic T cell receptorBispecific T-cell engagersCell therapyEarly phase clinical trialsYoung adultsConventional chemotherapeutic regimensDisease-related deathT-cell engagersClass of therapyT cell receptorCare of childrenCheckpoint inhibitorsAdverse eventsMetastatic diseaseSystemic treatmentChemotherapeutic regimensSurgical interventionClinical trials